DMK PHARMACEUTICALS Corp: Nasdaq/NYSE listing notice — Adamis receives Nasdaq delisting notice for bid-price non-compliance; plans appeal

DMK PHARMACEUTICALS Corp

Nasdaq Staff issued delisting determination on Dec 28, 2022, for failure to meet minimum bid price under Rule 5550(a)(2).
Company had two 180-day grace periods through Dec 27, 2022, but did not regain compliance.
Adamis will timely request a hearing before the Nasdaq Hearings Panel, which stays delisting pending decision.
If delisted, shares would be eligible to trade on the OTC Markets platform.
No assurance that the Panel will grant continued listing or additional compliance extension.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 28, 2022, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) as of December 27, 2022, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any furth

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001387131-22-012903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.